Feasibility and Utility of Anatomical and Physiological Evaluation of Coronary Disease With Cardiac CT in Severe Aortic Stenosis (FUTURE-AS Registry): Rationale and Design

• Published in: Journal of the Society for Cardiovascular Angiography & Interventions 2024-03, Vol.3 (3), p.101293, Article 101293
• Main Authors: Khoo, John King, Sellers, Stephanie, Fairbairn, Timothy, Polsani, Venkateshwar, Liu, Shizhen, Yong, Gerald, Shetty, Sharad, Corrigan, Frank, Ko, Brian, Vucic, Esad, Fitzgibbons, Timothy P., Kakouros, Nikolaos, Blanke, Philipp, Sathananthan, Janarthanan, Webb, John, Wood, David, Leipsic, Jonathon, Ihdayhid, Abdul Rahman
• Format: Article
• Language: English
• Subjects: aortic stenosis; computed tomography coronary angiography; coronary artery disease; fractional flow reserve derived from computed tomography; transcatheter aortic valve replacement
• ISSN: 2772-9303; 2772-9303
• DOI: 10.1016/j.jscai.2023.101293

Coronary artery disease (CAD) in patients with severe aortic stenosis (AS) is common and may be associated with worse outcomes. Computed tomography coronary angiography (CTCA) and fractional flow reserve derived from computed tomography (FFRCT) are tools for comprehensive coronary assessment. The utility and safety of CTCA and FFRCT in the work-up for transcatheter aortic valve replacement (TAVR) is not established, especially in an evolving landscape that involves younger TAVR patients. The FUTURE-AS Registry will assess the utility and safety of cardiac-optimized CTCA and FFRCT to evaluate CAD and guide referral for downstream invasive coronary angiography (ICA) in patients with severe AS being considered for TAVR. FUTURE-AS is an international, prospective, multicenter registry of patients with severe AS referred for TAVR being assessed for CAD with CTCA and FFRCT. The primary end point is the per-patient sensitivity and negative predictive value of CTCA and FFRCT for identifying anatomical and physiologically significant CAD compared to ICA and invasive FFR. The safety end point is the incidence of symptomatic hypotension or bradycardia requiring intervention following the administration of nitroglycerin or β-blocker medications. Feasibility end points include the incidence of noninterpretable CTCA scans and CTCA scans not adequate for FFR analysis. Other utility end points include specificity, positive predictive value, and accuracy of CTCA and FFRCT. Lastly, the potential of a CTCA and FFRCT guided strategy to defer pre-TAVR ICA will be assessed. FUTURE-AS will characterize the utility, safety, and feasibility of CTCA and FFRCT for coronary assessment pre-TAVR. [Display omitted]